Skip to main content
Top
Published in: Tumor Biology 7/2014

01-07-2014 | Research Article

May increased CA125 in borderline ovarian tumor be indicative of a poor prognosis? A case report

Authors: Emanuela Anastasi, Maria Grazia Porpora, Irene Pecorella, Silvia Bernardo, Luigi Frati, Pierluigi Benedetti Panici, Lucia Manganaro

Published in: Tumor Biology | Issue 7/2014

Login to get access

Abstract

We present a case of a 58-year-old menopausal woman referred to our hospital for the presence of large pelvic masses diagnosed by clinical examination and pelvic ultrasound. MRI examination showed voluminous bilateral capsulated multilocular ovarian cysts slightly hyperintense on T1-weighted images with thick septa and small papillary projections. CT scan confirmed the MRI findings. Among the ovarian tumor markers analyzed (CA125, HE4, and CA72.4), only Ca125 was slightly increased (48 U/ml). These data were suggestive of mucinous ovarian tumor. The patient underwent total hysterectomy with bilateral salpingo-oophorectomy, appendectomy, and multiple peritoneal biopsies. Pathological examination revealed bilateral borderline mucinous ovarian tumor with superficial atypical implants. Nine months later, the patient complained of left coxofemoral pain and underwent a PET/TC total body that suggested pubic bone metastases. Ovarian tumor markers were analyzed, and a second PET/TC was performed. CA125 was 252 U/ml, HE4 62 pM/L, and CA72.4 > 100 U/Ml. PET/TC was suggestive of peritoneal carcinosis. The patient was readmitted to the hospital. Clinical examination revealed small vaginal nodules. All nodules were excised. Microscopic analysis of all specimens revealed metastatic mucinous adenocarcinoma of intestinal type.
The case shows that even a slight CA125 increase in the presence of a borderline ovarian tumor should not be overlooked since it can be indicative of a progressive disease. This case also highlights its additional diagnostic value when serum CA125 analysis is used in conjunction with MRI and CT imaging for the prognosis of mucinous borderline ovarian tumors (mBOTs).
Literature
1.
go back to reference Messalli EM, Grauso F, Balbi G, Napolitano A, Seguino E, Torella M. Borderline ovarian tumors: features and controversial aspects. Eur J Obstet Gynecol Reprod Biol. 2013;167(1):86–9.CrossRefPubMed Messalli EM, Grauso F, Balbi G, Napolitano A, Seguino E, Torella M. Borderline ovarian tumors: features and controversial aspects. Eur J Obstet Gynecol Reprod Biol. 2013;167(1):86–9.CrossRefPubMed
2.
go back to reference Acs G. Serous and mucinous borderline (low malignant potential) tumors of the ovary. Am J Clin Pathol. 2005;123:S13–57.PubMed Acs G. Serous and mucinous borderline (low malignant potential) tumors of the ovary. Am J Clin Pathol. 2005;123:S13–57.PubMed
3.
go back to reference Midulla C, Manganaro L, Longo F, Viggiani V, Frati L, Granato T, et al. HE4 combined with MDCT imaging is a good marker in the evaluation of disease extension in advanced epithelial ovarian carcinoma. Tumor Biol. 2012;33(5):1291–8.CrossRef Midulla C, Manganaro L, Longo F, Viggiani V, Frati L, Granato T, et al. HE4 combined with MDCT imaging is a good marker in the evaluation of disease extension in advanced epithelial ovarian carcinoma. Tumor Biol. 2012;33(5):1291–8.CrossRef
4.
go back to reference 4) Burkholz K J, Wood B P, Zuppan C. RadioGraphics: borderline papillary serous tumor of the right ovary. 2005; 25: 1689–1692 4) Burkholz K J, Wood B P, Zuppan C. RadioGraphics: borderline papillary serous tumor of the right ovary. 2005; 25: 1689–1692
5.
go back to reference Cusido M, Balaguero L, Hernandez G, Falcon O, Rodriguez-Escudero FJ, Vargas JA, et al. Results of the national survey of borderline ovarian tumors in Spain. Gynecol Oncol. 2007;104:617–22.CrossRefPubMed Cusido M, Balaguero L, Hernandez G, Falcon O, Rodriguez-Escudero FJ, Vargas JA, et al. Results of the national survey of borderline ovarian tumors in Spain. Gynecol Oncol. 2007;104:617–22.CrossRefPubMed
6.
go back to reference Anastasi E, Granato T, Falzarano R, Storelli P, Ticino A, Frati L, et al. The use of HE4, CA125 and CA72-4 biomarkers for differential diagnosis between ovarian endometrioma and epithelial ovarian cancer. J Ovarian Res. 2013;6(1):44.PubMedCentralCrossRefPubMed Anastasi E, Granato T, Falzarano R, Storelli P, Ticino A, Frati L, et al. The use of HE4, CA125 and CA72-4 biomarkers for differential diagnosis between ovarian endometrioma and epithelial ovarian cancer. J Ovarian Res. 2013;6(1):44.PubMedCentralCrossRefPubMed
7.
go back to reference Marcus CS, Maxwell GL, Darcy KM, Hamilton CA, McGuire WP. Current approaches and challenges in managing and monitoring treatment response in ovarian cancer. J Cancer. 2014;5(1):25–30.PubMedCentralCrossRefPubMed Marcus CS, Maxwell GL, Darcy KM, Hamilton CA, McGuire WP. Current approaches and challenges in managing and monitoring treatment response in ovarian cancer. J Cancer. 2014;5(1):25–30.PubMedCentralCrossRefPubMed
Metadata
Title
May increased CA125 in borderline ovarian tumor be indicative of a poor prognosis? A case report
Authors
Emanuela Anastasi
Maria Grazia Porpora
Irene Pecorella
Silvia Bernardo
Luigi Frati
Pierluigi Benedetti Panici
Lucia Manganaro
Publication date
01-07-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 7/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-1898-9

Other articles of this Issue 7/2014

Tumor Biology 7/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine